Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward

腹侧被盖区神经元的异质性和阿片类药物奖励

基本信息

项目摘要

DESCRIPTION (provided by applicant): Approximately 2 million people are dependent on or abuse opioids in the USA each year (www.dhhs.gov), and NIDA reports that illicit opiate use is on the rise. Accumulating evidence indicates that alcohol consumption and rewarding events cause the release of endogenous opioids in the brain, therefore utilizing the same mu opioid receptors (MORs) and brain circuits involved in opiate addiction. In spite of the magnitude of this problem, we only partially understand how MOR activation causes reward and leads to addiction. Therefore overall objective of this proposal is to investigate the circuits that contribute to opioid reward. MORs in the ventral tegmental area (VTA) are required for morphine reward (Olmstead and Franklin, 1997b; Zhang et al., 2009). VTA neurons release dopamine in the ventral striatum, and it is commonly thought that dopamine released in the ventral striatum causes opioid reward. Yet, lesions of the ventral striatum do not block morphine reward (Olmstead and Franklin, 1996, 1997a; White et al., 2005). Instead, lesions of the medial prefrontal cortex (mPFC) do block morphine reward (Tzschentke and Schmidt, 1999). Therefore the proposed experiments focus on MOR control of mPFC-projecting VTA neurons. Detailed anatomy of this projection will be studied, in particular to test whether the newly discovered VTA glutamate neurons project to the mPFC. Because morphine reward is dopamine-independent in opiate na¿ve animals (Bechara et al., 1992; Nader and van der Kooy, 1997), it is critical to determine the effects of MOR activation on both the non-dopamine and dopamine VTA neurons that project to the mPFC. Cortical-projecting neurons will be retrogradely labeled so that they can be identified during brain slice recordings, and pre- and postsynaptic MOR agonist effects will be measured electrophysiologically in these labeled neurons. Following recordings, the neurotransmitter content of the recorded neurons will be directly identified as dopamine, glutamate, or GABA using immunocytochemistry or in situ hybridization. Since electrical stimulation of the mPFC is rewarding (Corbett et al., 1982; Duvauchelle and Ettenberg, 1991), it is hypothesized that MOR activation will excite mPFC-projecting dopamine and glutamate neurons, and inhibit GABA neurons. By improving our understanding of the circuitry involved in opioid reward, this work will enable more effective therapeutic development for disorders that involve VTA and mPFC signaling, including addiction, alcoholism, impulsivity disorders and attention deficit hyperactivity disorder. PUBLIC HEALTH RELEVANCE: The overall goal of the proposed research is to determine the underlying brain circuitry responsible for opiate addiction. Because brain opiate receptors are also activated following alcohol consumption, food consumption, and other natural rewards, the same circuitry also contributes to other disorders such as alcoholism and overeating. By determining the brain pathways involved in opiate reward and addiction, this work will enable more targeted treatments to be developed for these addiction disorders.
描述(由申请人提供):在美国,每年约有200万人依赖或滥用阿片类药物(www.dhs.gov),NIDA报告称,非法阿片类药物的使用正在增加。越来越多的证据表明,饮酒和奖励事件导致大脑中内源性阿片类药物的释放,因此利用与阿片成瘾有关的相同的MU阿片受体(MORS)和大脑回路。尽管这个问题很严重,但我们对MOR的激活如何导致奖赏和成瘾只有部分了解。因此,这项提议的总体目标是调查有助于阿片类药物奖励的回路。吗啡奖赏需要腹侧被盖区(VTA)的MORS(Olmstead和Franklin,1997b;Zhang等,2009)。VTA神经元在腹侧纹状体释放多巴胺,通常认为腹侧纹状体释放的多巴胺引起阿片类奖赏。然而,腹侧纹状体的损伤并不能阻止吗啡奖励(Olmstead和Franklin,1996,1997 a;White et al.,2005)。相反,内侧前额叶皮质(MPFC)的损伤确实阻断了吗啡奖励(Tzschentke和Schmidt,1999)。因此,本实验的重点是对投射mPFC的VTA神经元进行MOR控制。对这一投射的详细解剖将被研究,特别是测试新发现的VTA谷氨酸神经元是否投射到mPFC。由于吗啡奖赏在鸦片类NA动物中是不依赖多巴胺的(Bechara等人,1992;Nader和van der Kooy,1997),因此确定MOR激活对投射到mPFC的非多巴胺和多巴胺VTA神经元的影响是至关重要的。皮质投射神经元将被逆行标记,以便在脑片记录中识别它们,并将在这些标记的神经元中测量突触前和突触后的MOR激动剂效应。在记录之后,记录的神经元的神经递质含量将通过免疫细胞化学或原位杂交被直接鉴定为多巴胺、谷氨酸或GABA。由于电刺激mPFC是有回报的(Corbett等人,1982;Duvuchelle和Ettenberg,1991),因此假设MOR激活将兴奋mPFC投射多巴胺和谷氨酸的神经元,并抑制GABA神经元。通过提高我们对阿片类药物奖励所涉及的电路的理解,这项工作将使涉及VTA和mPFC信号的疾病的治疗开发成为可能,包括成瘾、酒精中毒、冲动障碍和注意缺陷多动障碍。 与公共健康相关:拟议研究的总体目标是确定导致阿片成瘾的潜在大脑回路。由于大脑阿片受体在饮酒、进食和其他自然奖励后也会被激活,同样的电路也会导致其他疾病,如酗酒和暴饮暴食。通过确定参与鸦片奖励和成瘾的大脑通路,这项工作将使人们能够为这些成瘾障碍开发更有针对性的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elyssa Margolis其他文献

Elyssa Margolis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elyssa Margolis', 18)}}的其他基金

A highly opioid responsive VTA projection to the dorsal endopiriform nucleus.
高度阿片类药物反应的 VTA 投射到背内核状核。
  • 批准号:
    10739039
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
Resolving differences between clinical opioids at single neurons
解决临床阿片类药物在单个神经元上的差异
  • 批准号:
    10355433
  • 财政年份:
    2021
  • 资助金额:
    $ 38.2万
  • 项目类别:
Understanding endogenous opioid drive of alcohol consumption
了解饮酒的内源性阿片类药物驱动力
  • 批准号:
    10190738
  • 财政年份:
    2018
  • 资助金额:
    $ 38.2万
  • 项目类别:
Understanding endogenous opioid drive of alcohol consumption
了解饮酒的内源性阿片类药物驱动力
  • 批准号:
    10436820
  • 财政年份:
    2018
  • 资助金额:
    $ 38.2万
  • 项目类别:
The role of the VTA-lateral habenula circuit in opioid mediated behaviors
VTA-外侧缰核回路在阿片类药物介导的行为中的作用
  • 批准号:
    10198878
  • 财政年份:
    2017
  • 资助金额:
    $ 38.2万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8582542
  • 财政年份:
    2013
  • 资助金额:
    $ 38.2万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8681802
  • 财政年份:
    2013
  • 资助金额:
    $ 38.2万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8026051
  • 财政年份:
    2011
  • 资助金额:
    $ 38.2万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8409810
  • 财政年份:
    2011
  • 资助金额:
    $ 38.2万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 38.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 38.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 38.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了